MedTrace Logo

Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma

NCT03121833 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2019-12-26

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled (2: 1), multicenter clinical phase II clinical trial evaluating the efficacy and safety of Endostar combined with chemotherapy for stage IV soft tissue sarcoma.

Conditions

  • Soft Tissue Sarcoma, Adult, Stage IIB

Interventions

DRUG

Endostar

Recombinant Human Endostatin Injection

DRUG

Placebo

500ml 0.9% sodium chloride

DRUG

AIM regimen / GT regimen

"Pirarubicin (THP) + Ifosfamide (IFO)" / "Docetaxel (TXT) + Gemcitabine (GEM)"

Sponsors & Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Principal Investigators

  • Jilong Yang, M.D., Ph.D. · Tianjin Medical University Cancer Institute and Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2019-12-20
Completion
2019-12-20

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03121833 on ClinicalTrials.gov